

Program

ADVANCES IN ALLOGENEIC
STEM CELL TRANSPLANTATION

May, 2nd - 4th 2013
Freiburg, Germany

Thursday May 2nd 2013

14:30h Opening - Welcome address

Dean Medical Faculty Freiburg, Prof. Blum
Head of the Department of Hematology,
Oncology and Stem cell transplantation, Prof. Duyster
Head Section Allogeneic Stem Cell Transplantation, Prof. Finke

15:00h Session - GvHD biology

Chair: *Andreas Beilhack, Arnold Ganser*

Novel Molecular Targets in Regulation of GVHD
Pavan Reddy, Michigan
Immunobiology of T cells in GVHD
Robert Negrin, Stanford
Antigen Presentation in GVHD
Warren Shlomchik, Yale
Current challenges in GvHD treatment
Gerard Socie, Paris

16:15h Coffee break

16:40h Session - Novel clinical developments for GvHD prevention

Chair: *Roland Mertelsmann, Ernst Holler*

Lymphocyte trafficking in graft-versus-host disease
Ran Reshef, Pennsylvania
Allogeneic hematopoietic stem cell transplantation in
AML-CR1: towards a personalized approach
Jan Cornelissen, Rotterdam
New strategies of immunomodulation after allogeneic
transplantation
Jose Perez-Simon, Sevilla

18:00h Session - Tailoring T cell responses - Gentransfer

Chair: *Justus Duyster, Charlotte Niemeyer*

Designer nuclease mediated gene editing in stem cells
Toni Cathomen, Freiburg
T-cell engineering in hematopoietic stem cell transplantation
Fabio Ciceri, Milano
T cell Therapy of Cancer
Hans Stauss, London

20:00h Dinner

Friday May 3rd 2013

8:30h Session - The intestinal immune system and GvHD

Chair: *Olaf Penack, Matthias Stelljes*


The microbiome and GvHD
Marcel van den Brink, New York
The role of local hypoxia and micro RNAs in intestinal GvHD
Robert Zeiser, Freiburg
Intestinal immune reconstitution and GvHD:
Lessons from serial biopsies
Ernst Holler, Regensburg
Apoptosis and neutrophils -
a role in multiple inflammatory diseases
Georg Häcker, Freiburg

10:30h Coffee break

11:00h Session - GvHD: prevention - treatment

Chair: *Martin Gramatzki, Martin Bentz*

IL-2 and other therapy for chronic GVHD
Robert Soiffer, Boston
Long-term risks for survivors of allogeneic stem cell trans-
plant recipients
Hans Messner, Toronto
Influence of antibody based in-vivo T cell depletion on post
transplant immune reconstitution.
Constantijn Halkes, Leiden
Evaluation of JAK1/2 inhibition in a GvHD model
Nikolas von Bubnoff, Freiburg



13:00h Lunch

14:00h Unrelated donors - mismatched donors

Chair: *Wolfgang Bethge, Brigitte Strahm*

Partially HLA-mismatched stem cell transplantation with
high dose, post-transplantation cyclophosphamide for
malignant and non-malignant hematologic disorders
Ephraim Fuchs, Baltimore
Has the time for haploidentical transplant arrive for all
patients? The Beijing experience
Xiao-Jun Huang, Peking
Haploidentical transplantation followed by antibody based
immunotherapy for advanced leukemia and neuroblastoma
Rupert Handgretinger, Tübingen
Prevention and treatment of relapse after allogeneic SCT in
children and adolescents
Peter Bader, Frankfurt

15:45h Coffee break

16:15h Session - Immunotherapy

Chair: *Andreas Mackensen, Peter Dreger*

The B-cell receptor and B-cell lymphomas: Novel insights
Hendrik Veelken, Leiden
Dissecting GVL and GVHD with 21st century tools
Edus Warren, Seattle
Patient-individualized production of leukemia-reactive CD4+
and CD8+ cytotoxic T lymphocytes
Wolfgang Herr, Regensburg
TCR nanoclusters regulate the sensitivity of T cell responses
Wolfgang Schamel, Freiburg

17:30h Excursion - Vesper

Saturday May 4th 2013

8:30h Session - NK cell therapy after allo-HCT

Chair: *Martin Bornhäuser, Bernhard Kremens*

Role of KIR and HLA class I ligands in HSCT
Markus Uhrberg, Düsseldorf
Adoptive immunotherapy using NK cells
Jacob Passweg, Basel
Expansion, phenotype and development of adoptively trans-
ferred and graft derived NK cells after haploidentical stem cell
transplantation
Lutz Uharek, Berlin
Alemtuzumab in conditioning: How Much Is Good Enough?
Alexandros Spyridonidis, Patras

10:00h Coffee break

10:30h Session - Novel developments: drugs & cellular therapy

Chair: *Donald Bunjes, Wolfgang Herr*

Relapse after SCT prevention is better than cure
John Barrett, Washington
AML relapse after alloSCT: new donor - new drugs?
Jürgen Finke, Freiburg
Clinical and experimental studies using fetal membrane
cells in HSCT
Olle Ringden, Stockholm
Lessons from adoptive T cell transfer
Hans Kolb, München

11:30h Session - Post-transplant infections

Chair: *Hartmut Bertz, Markus Ringhofer*

Advances in Prevention of Viral Infections in HCT Recipients
Michael Boeckh, Seattle
Immunoregulation in allogeneic SCT
Matthias Edinger, Regensburg
Immunotherapy to improve outcome of allo stem cell trans-
plantation
Herrmann Einsele, Würzburg

13:00h Lunch and Departures

Sponsors Speakers/Chairs

Platin Sponsor*



Silver Sponsor**



Exhibitor***



- Bader, Peter - *Frankfurt*
- Barrett, John - *Washington*
- Beilhack, Andreas - *Würzburg*
- Bentz, Martin - *Karlsruhe*
- Bertz, Hartmut - *Freiburg*
- Bethge, Wolfgang - *Tübingen*
- Boeck, Michael - *Seattle*
- Bornhäuser, Martin - *Dresden*
- Bunjes, Donald - *Ulm*
- Cathomen, Toni - *Freiburg*
- Ciceri, Fabio - *Milano*
- Cornelissen, Jan - *Rotterdam*
- Dreger, Peter - *Heidelberg*
- Duyster, Justus - *Freiburg*
- Edinger, Matthias - *Regensburg*
- Einsele, Hermann - *Würzburg*
- Finke, Jürgen - *Freiburg*
- Fuchs, Ephraim - *Baltimore*
- Ganser, Arnold - *Hannover*
- Gramatzki, Martin - *Kiel*
- Häcker, Georg - *Freiburg*
- Halkes, Constantijn - *Leiden*
- Handgretinger, Rupert - *Tübingen*
- Herr, Wolfgang - *Regensburg*
- Holler, Ernst - *Regensburg*
- Huang, Xiao-Jun - *Peking*
- Kolb, Hans - *München*
- Kremens, Bernhard - *Essen*
- Mackensen, Andreas - *Erlangen*
- Messner, Hans - *Toronto*
- Negrin, Robert - *Stanford*
- Niemeyer, Charlotte - *Freiburg*
- Passweg, Jacob - *Basel*
- Penack, Olaf - *Berlin*
- Perez-Simon, Jose Antonio - *Sevilla*
- Reddy, Pavan - *Michigan*
- Ringden, Olle - *Stockholm*
- Ringhoffer, Markus - *Karlsruhe*
- Rocha, Vanderson - *Oxford*
- Schamel, Wolfgang - *Freiburg*
- Shlomchik, Warren - *Yale*
- Socie, Gerard - *Paris*
- Soiffer, Robert - *Boston*
- Spyridonidis, Alexandros - *Patras*
- Stauss, Hans - *London*
- Stelljes, Matthias - *Münster*
- Strahm, Brigitte - *Freiburg*
- Uharek, Lutz - *Berlin*
- Uhrberg, Markus - *Düsseldorf*
- van den Brink, Marcel - *New York*
- Veelken, Hendrik - *Leiden*
- von Bubnoff, Nikolas - *Freiburg*
- Warren, Edus - *Seattle*
- Zeiser, Robert - *Freiburg*

* Platin Sponsor 25.000,-
** Silver Sponsor 10.000,-
*** Exhibitor 1.800,-

Organizer

Universitätsklinikum Freiburg
Hugstetter Str. 55 · 79106 Freiburg

In cooperation with

kongress & kommunikation gGmbH
Hanferstr. 4 · 79108 Freiburg
Telefon +49 (0)761 21 68 08 16
eMail: khonsari@kongress-kommunikation.de
www.kongress-kommunikation.de



Conference Venue

Historisches Kaufhaus
Münsterstraße 24 · 79098 Freiburg im Breisgau

THE CONFERENCE IS FREE OF CHARGE.

Registration

For the conference please register at:
www.allosct-freiburg.de

© PPAFF-design.de Bilder: ©fotolia.com @FWTM/FR



ADVANCES IN ALLOGENEIC
STEM CELL TRANSPLANTATION

May, 2nd - 4th 2013
Freiburg, Germany

Dear colleagues,

It is our pleasure to invite you, after an interval of 4 years, back to Freiburg for the "Advances in allogeneic stem cell transplantation" meeting. In this meeting we will try to bring together basic and translational science as well as approaches that transfer knowledge into early clinical studies. Since the last meeting in 2009, the field of allogeneic stem cell transplantation has substantially developed and new insights into the biology of graft-versus-host disease and immune reconstitution have been transferred into clinical trials using cytokine treatment or chemokine receptor inhibition to tailor the allogeneic immune response. Furthermore alternative graft sources and large international donor registries have helped to find a suitable graft for virtually all patients.

To cover major topics we have invited national and international experts working in the field of allogeneic stem cell transplantation focussing e.g. on the role of the intestinal immune system in GvHD, the immunobiology of T cells in GvHD, haploidentical or partially HLA-mismatched stem cell transplantation, clinical strategies to prevent GvHD, T-cell engineering by gene transfer, adoptive T cell and NK cell transfer strategies and management of post-transplant infections. Beside the planned oral presentations in the city of Freiburg we will also have free time for more informal discussion e.g. during a trip in the Black Forest area.

We cordially invite you to present your scientific findings, to participate in the discussion and to exchange ideas and concepts. We look forward to welcome you in Freiburg in May 2013.

From the organizers

Robert Zeiser and Jürgen Finke

ADVANCES IN ALLOGENEIC
STEM CELL TRANSPLANTATION

May, 2nd. - 4th. 2013
Freiburg , Germany